At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Robert A. Figlin, MD, deputy director at Cedars-Sinai Cancer and genitourinary tumor chair of the Editorial Board of the journal 

, about findings from the phase 2 KEYNOTE-564 trial (NCT03142334) with pembrolizumab (Keytruda) vs placebo in patients with histologically confirmed clear cell renal cell carcinoma following nephrectomy.

Although the data appear promising and have the potential to influence the standard of care in the future, Figlin noted that there are some concerns regarding data collection and questions left unanswered by the study’s results.

Late breaking abstract number 5 that was presented by Toni Choueiri, [MD,] from Dana-Farber, which looked at Keytruda in patients with high-risk resected disease, [demonstrated] an improvement in disease-free survival [DFS] when compared with placebo. [This] is a population of patients [who are] worth looking at and [this] is potentially practice changing. But there are a few observations that I would like to make…which were not really asked and addressed in the context of the discussion.

First of all, usually when we think about adjuvant treatment, we think about adjuvant treatment for high-risk, resected RCC where the only commercially available drug approved in that setting is sunitinib [Sutent] from the phase 3 S-TRAC trial [NCT00375674]. The trial that was presented by [Choueiri] included both high-risk, resected [disease], as well as a population of patients with known metastatic disease who were thought to have oligometastatic resections, rendering them disease free. I want to be clear that this is not a population of patients who [are] usually considered for adjuvant trials. In fact, it may skew the results in a way that favors the therapy. Why?

When one looks at the progression-free survival curves that were presented as part of ASCO, the curve separated very early and stayed separated over the course of the first 24 months. What one might want to ask is, even though about 6% of patients had metastatic disease that was resected, was the [immuno-oncology] therapy really benefiting that population without a clear signal yet in the high-risk, resected non-metastatic patient population? I think that the trial, while positive, is a bit flawed. Additionally, that could have been clarified with a better control of imaging—having blinded imaging at the beginning of the trial—to make sure that we all agree it was basically investigator-assessed outcomes. While I think that is important in general, one has to be very careful when [including] a population of patients who also have known, [biopsy-proven] metastatic disease. DFS, although possibly appropriate without independent radiologic review for a high-risk, resected patient [in the adjuvant setting], is generally not a form that we would take for the patients with known metastatic disease. [It was an] interesting trial [that was] potentially practice changing; certainly different than what we saw with targeted therapy in this setting; not yet in peer-reviewed publications for all of us to look at; and has some challenges that are going to make it a bit difficult to interpret. We are going to have to be looking for other adjuvant trials in a more ‘pure’ high-risk, resected population to assert that this is really practice changing.

Choueiri TK, Tomczak P, Park SH, et al. Pembrolizumab vs placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: randomized, double-blind, phase 3 KEYNOTE-564 study. 

. 2021;39(suppl 15):LBA5. doi:10.1200/JCO.2021.39.15_suppl.LBA5

Videos

CancerNetwork® sat down with Robert A. Figlin, MD, at the 2021 ASCO Annual Meeting to discuss the results of the KEYNOTE-564 trial with adjuvant pembrolizumab in patients with resected clear cell renal cell carcinoma. 

Robert A. Figlin, MD, Spotlights Key Findings With Adjuvant Pembrolizumab in Resected Clear Cell RCC From ASCO 2021

Findings from a cohort study of patients with primary colorectal cancer (CRC) revealed that a young onset of disease was associated with better survival compared with later-life occurrence when adjusting for tumor stage at diagnosis, according to findings published in 

This study used data collected from the National Cancer Database (NCDB) and included individuals up to 90 years of age, with those who were diagnosed between ages 51 and 55 selected as the later-onset reference group. Early-onset disease was defined as occurring at any age younger than 50 years.

“In this cohort study using a large US database, we observed an increase in incident CRC diagnoses at age 50 years, with an increased proportion of individuals with earlier-stage disease and a transient decrease in mortality,” wrote the study investigators.

Investigators studied 769,871 patients with CRC, of whom 102,168 (13.3%) had early-onset CRC and 78,812 (10.2%) had later-onset CRC. Patients diagnosed with early-onset CRC were more likely to be female, at 47.3% vs 43.8% of the later-onset group (

 < .001). Those with early-onset disease were also more likely to be diagnosed with stage IV (27.8%) vs later onset (24.1%); 

Individuals diagnosed with early-onset CRC experienced inferior overall survival, with a lower 10-year rate of 53.6% (95% CI, 53.2%-54.0%) vs 54.3% (95% CI, 53.8%-54.8%) in those with later-onset disease (

 < .001). However, those with early-onset CRC had higher survival rates across all years of follow-up when survival was stratified by stage. Individuals with early-onset CRC also had a reduction in mortality by a progressive multivariable adjustment analysis (HR, 0.95; 95% CI, 0.93-0.96; 

Looking at a subgroup of patients receiving a diagnosis from 35 to 39 years, showed the greatest mortality reduction (adjusted HR, 0.88; 95% CI, 0.84-0.92; 

 < .001). This compared favorably with the subgroups of patients ages 20 to 24 years (adjusted HR, 1.04; 95% CI, 0.88-1.22; 

 = .66) and younger than 20 years (HR, 1.04; 95% CI, 0.88-1.22; 

One limitation noted was the gap in cancer screenings from ages 49 to 50 years resulted in higher rates of diagnosis in the latter group. In addition, the NCDB did not make data available regarding causes of death, meaning investigators could not specify CRC-specific mortality.

“Our findings may have policy implications and may inform the current debate on whether to decrease the age of initial CRC screening,” wrote the study authors.

Investigators conclude that more attention should be given to younger patients to detect the disease at an early stage. These findings should be interpreted cautiously because further studies are needed to understand the heterogeneity of survival by age for patients with early-onset CRC.

Cheng E, Blackburn HN, Ng K, et al. Analysis of survival among adults with early-onset colorectal cancer in the national cancer database. 

. 2021;4(6):e2112539. doi:10.1001/jamanetworkopen.2021.12539

Articles

Individuals with an early-onset colorectal cancer diagnosis had a survival benefit versus those at later ages, especially for patients younger than 50 years old. 

Early-Onset Colorectal Study Shows Better Overall Survival for Patients Under 50

is a medical oncologist/hematologist and medical director of oncology at Morrison Cancer Center, Mary Lanning Healthcare in Hastings, Nebraska, and is a professor at the University of Nebraska Medical Center adjunct faculty. He is also an Editorial Advisory Board member at 

is the medical director of the Molecular Diagnostics Laboratory at University of Nebraska Medical Center, and associate professor at the University of Nebraska Medical Center Department of Pathology and and Microbiology.

is assistant professor, Department of Surgical Oncology, University of Nebraska Medical Center, Omaha, Nebraska.

 is a pathologist at Mary Lanning Healthcare.

 is a board certified general surgeon at Morrison Cancer Center, Mary Lanning Healthcare.

is a radiologist at Morrison Cancer Center, Mary Lanning Healthcare.

is a pathologist at Mary Lanning Healthcare.

Appendiceal mucinous neoplasms are a rare and heterogeneous group of diseases with challenging clinical management decisions. They account for less than 1% of all cancers but their incidence is on the rise. Treatment is based on their stage and histology. Appendiceal neoplasms frequently metastasize inside the abdomen; this leads to tumor cell growth in the abdominal cavity, known as peritoneal carcinomatosis, and buildup of mucinous material, known as pseudomyxoma peritonei. While low‐grade, early-stage tumors can be effectively treated with limited surgical resection, patients with low-grade, advanced-stage disease require peritoneal debulking and hyperthermic intraperitoneal chemotherapy. Therapeutic options for high-grade, advanced-stage mucinous tumors of the appendix have not been well established. Debulking surgery with hyperthermic intraperitoneal chemotherapy preceded and/or followed by systemic chemotherapy has been utilized based on some prospective but not randomized data. We present a case of mucinous adenocarcinoma of the appendix treated with neoadjuvant chemotherapy followed by cytoreductive surgery/hyperthermic intraperitoneal chemotherapy and adjuvant chemotherapy. Preoperative chemotherapy provided a favorable histologic response by converting initial mucinous appendiceal adenocarcinoma histology to a high-grade mucinous appendiceal neoplasm.

Appendiceal epithelial neoplasms, peritoneal carcinomatosis, hyperthermic intraperitoneal chemotherapy.

A White woman, aged 65 years, presented with pain and fullness in her lower abdomen. Initial evaluation, including gynecologic exam and a CT scan of the abdomen and pelvis, showed a heterogeneous centrally located uterus with a possible semisolid hematoma, submucosal fibroid, or a polyp. Further evaluation with a transvaginal ultrasound reported a 3.5 × 3.8 × 2.7-cm uterine mass. Endometrial biopsy was negative for hyperplasia or malignancy. She was scheduled for a laparoscopic hysterectomy, which was delayed due to COVID-19 infection and patient nonadherence. Six months from the original presentation, she was taken to the operating room for laparoscopic hysterectomy. During the procedure, she was noted to have carcinomatosis throughout the abdomen with findings of omental caking. The procedure was changed to a diagnostic laparoscopy. The appendix appeared to be obliterated on the tip with inflammatory tissue and inflamed fat around the tip. The base of the appendix and cecum was visualized and looked normal. Peritoneal and omental biopsies were taken. Postprocedure restaging CT scan of the abdomen and pelvis showed induration within the anterior peritoneal fat, representing peritoneal carcinomatosis and prominence of the appendix (

). Upper and lower endoscopies were negative. Pathology of the left peritoneal wall and omentum biopsy was consistent with moderately differentiated adenocarcinoma with mucin present intracellularly. Immunohistochemical stains for pankeratin, cytokeratin 20, and CDX2 were positive(

), whereas stains for synaptophysin, cytokeratin 7, calretinin, and PAX8 were negative. MLH1, PMS2, MSH2, and MSH6 protein expression was retained. A next-generation sequencing companion diagnostic assay showed no FDA-approved targetable alteration but 1 genomic finding of a pathogenic 

 p.D594G mutation. PD-L1 immunohistochemistry analysis revealed tumor proportion score of 0% (FoundationOne CDx).

Induration within the anterior peritoneal fat representing peritoneal carcinomatosis

 Prominence of appendix possible underlying lesion

Omentum biopsy showing neoplastic cells dissecting through fibroadipose tissue (hematoxylin and eosin, 400x magnification)

Immunoperoxidase stain for CDX2 (400x magnification)

Immunoperoxidase stain for CK20 (400x magnification)

Based on the multidisciplinary tumor board consensus, she was treated with neoadjuvant chemotherapy of 5-fluorouracil (5-FU), folinic acid, and oxaliplatin (FOLFOX) and bevacizumab (Avastin) for 6 cycles, to be followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). After neoadjuvant therapy, restaging CT scans revealed decreased omental fat stranding and a mildly dilated appendix. She underwent CRS with right hemicolectomy, small bowel resection, cholecystectomy, peritonectomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy followed by HIPEC. Pathology revealed no evidence of tumor in the ileum or colon but high-grade appendiceal mucinous neoplasm (HAMN) involving the distal half of the appendix with invasion through the muscle wall into the adjoining periappendiceal fibroadipose tissue with extensive acellular mucin areas and focal signet-ring cell differentiation. Twenty-eight regional lymph nodes were negative. There was no lymphovascular or perineural invasion. Uterus revealed focal adenomyosis and atypical hyperplasia of the endometrium but no evidence of mucinous neoplasm. Ovaries showed focal acellular mucin and focal low-grade mucinous neoplasm on the surface without penetration into the ovarian stroma. Pathologic stage was pT4a (tumor invades through the visceral peritoneum), pN0 (no regional lymph node metastasis),pM1b (intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells).

Cancers of the appendix are extremely rare, with an estimated incidence of 0.15 to 0.9 per 100,000 people. Appendiceal mucinous neoplasms comprise 0.2% to 0.3% of appendectomy specimens. Affecting men and women equally, the average age of onset is between 50 and 55 years.

 Clinical presentation can be an appendicitis, a hernia filled with mucin, an abdominal/pelvic mass, or an incidental finding on some form of imaging study or during a surgical procedure for an unrelated indication. In women, these neoplasms often spread to the ovaries and can easily be confused with ovarian cancer. A majority (65%) of appendiceal tumors are of neuroendocrine origin. Adenocarcinomas (mucinous, nonmucinous, or signet-ring) constitute approximately 20% of these tumors.

 Treatment of appendiceal tumors depends on the extent and the histology of the disease. Systemic chemotherapy and cytoreductive surgery have long been used to treat macroscopic disease. Addition of HIPEC to CRS has become a novel approach to eradicate both macroscopic and microscopic residual tumor tissue in the abdomen. The treatment of appendiceal mucinous neoplasms has not been well defined, with controversies regarding pre- and postoperative chemotherapy, extent of surgery, role of early postoperative intraperitoneal chemotherapy, and HIPEC. Here, we present a review of the histologic and clinical spectrum of epithelial neoplastic mucinous lesions of the appendix.

The appendix can be home to several distinctive benign and malignant pathologies with variable histologic classifications. Accurate histologic diagnosis of appendiceal neoplasms can be quite challenging. A complete examination of the entire specimen and rigorous evaluation of the appendiceal wall for any evidence of epithelial invasion are crucial to distinguish between adenocarcinomas and all other types of mucinous lesions. In 2016, an international panel of pathologists and clinicians—the Peritoneal Surface Oncology Group International (PSOGI)—came together to categorize noncarcinoid epithelial tumors of the appendix.

 The current pathological classification schemes for neoplastic lesions of the appendix take into account both the variations of the histopathological appearance and the pattern of mural involvement in the epithelium. Neoplastic appendiceal mucinouslesions consist of serrated polyps (hyperplastic lesions with or without dysplasia), hyperplastic polyps, low-grade appendiceal mucinous neoplasms, high-grade appendiceal mucinous neoplasms, and mucinous adenocarcinomas with or without signet-ring cell carcinomas (

 Epithelial Neoplastic Appendiceal Mucinous Lesions

Historically, hyperplastic lesions have been considered to be reactive in nature. Most of them lack cytological atypia/dysplasia and typically involve the mucosa circumferentially. Serrated polyps of the appendix, with or without dysplasia, remain incompletely studied and are not always classified as neoplasms. Due to the lack of certainty about their biological nature, it has been suggested that these lesions should be classified as serrated polyps, either with or without epithelial dysplasia, rather than using the term adenoma, a term that would more specifically classify them as benign neoplasms.

 Low-grade appendiceal mucinous neoplasms (LAMNs) are true neoplasms, with dysplastic epithelium and expansile growth, but they lack overt infiltrative epithelial invasion of the appendiceal wall.

 They remain mostly confined to the muscularis propria. Due to their expansile growth pattern, however, they may push and cause the thinning and rupture of the appendiceal wall; this can result in spillage of cellular or acellular mucin, leading to pseudomyxoma peritonei (PMP). HAMNs are defined by the degree of epithelial dysplasia, including cribriform growth, nuclear stratification to the surface of the epithelium, and hyperchromatic and pleomorphic nuclei with ample atypical mitotic activity.

 Mucinous adenocarcinomas of the appendix are described as infiltrative lesions with invasive pattern, and they typically have a marked desmoplastic stromal reaction. They can be mucinous or nonmucinous.

 Similar to other adenocarcinomas, they are categorized into well-, moderately, or poorly differentiated histologies. The presence of signet-ring cells denotes the poorly differentiated category. While well-differentiated mucinous adenocarcinomas are more likely to produce peritoneal spread with a clinical picture of PMP, the higher-grade tumors present with peritoneal carcinomatosis and distant metastasis.

Immunohistochemistry and Molecular Diagnostics

Published in 2019, the 5th edition of current World Health Organization classification of appendiceal tumors is largely based on the tumors’ histologic appearance and does not include their immunohistochemistry features or molecular pathology.

 Mucinous neoplasms of various sites, including gastrointestinal, breast, lung, pancreas, and gynecologic, all can present with very similar histomorphologic appearances and frequently metastasize to the peritoneal surface, ovary, liver, or lung, which makes the identification of the primary site rather difficult.

 All mucinous neoplasms express low-molecular-weight cytokeratins (CKs), such as CK7, CK8, CK18, and CK20.

 While most mucinous neoplasms of the lower gastrointestinal tract express CK20, and most nongastrointestinal mucinous neoplasms express CK7, the reverse can be true: CK20 can be expressed in 47% to 83% of ovarian mucinous neoplasms, and CK7 can be expressed in 37% of appendiceal mucinous neoplasms.

 CDX2, a transcription factor regulating intestinal epithelial cell differentiation, is strongly expressed in gastrointestinal epithelial tumors, including appendiceal mucinous neoplasms.

 PAX8, a very specific ovarian mucinous neoplasm marker, is not commonly expressed in appendiceal neoplasms.

 SATB2, a 733–amino acid human DNA-binding protein involved in transcriptional regulation and chromatin remodeling, has been shown to have highly restricted expression to glandular cells lining the lower gastrointestinal tract, including appendiceal mucinous neoplasms.

Hyperplastic polyps and serrated lesions with or without dysplasia often have 

 mutations. LAMNs and HAMNs share high rates of 

 comutations but are usually wild-type for 

 mutations may drive progression to a more advanced phenotype.

 Appendiceal adenocarcinomas frequently harbor mutations in 

. They can also have significant nuclear expression of β-catenin, loss of nuclear or nuclear and cytoplasmic expression of SMAD4, and loss of cytoplasmic membranous expression of E-cadherin. Recent identification of heterozygous 

, and NOTCH4 germline mutations in LAMNs and HAMNs suggest a hereditary predisposition; however, microsatellite instability does not seem to have a role in the pathogenesis of epithelial appendiceal neoplasms and is rarely detected in these tumors.

 mutation occurs within the highly conserved DFG motif of the kinase domain of the BRAF protein and is a class 3 inactivating mutation (kinase impaired). It is likely insensitive to vemurafenib (Zelboraf).

 However, it leads to increased activation of ERK signaling through CRAF-RAS pathways and has been postulated to be potentially responsive to receptor tyrosine kinase or MEK inhibition, although more studies are required.

 This mutation has been shown to occur somatically in a diverse set of tumors, including lung, melanoma, and colorectal cancers.

Clinical presentation is usually asymptomatic or with rather nonspecific symptoms. Acute or chronic right lower quadrant abdominal pain, occasionally a palpable abdominal mass, or, less commonly, intermittent colicky abdominal pain and/or gastrointestinal bleeding associated with intussusception of a mucocele, can be initial presenting symptoms. Intestinal obstruction from mass effect, genitourinary symptoms, or acute abdomen from mucocele rupture or sepsis are other possible presentations.

 At the time of diagnosis, appendiceal cancer can be either localized to the appendix or may have already spread to the abdominal cavity and peritoneum. Because of the appendix’s thin-wall anatomy, these neoplasms are more likely to have spread at the time of initial diagnosis. Mucinous lesions due to hyperplasia (serrated polyps) or retention cysts (simple mucoceles) are not associated with recurrence once they rupture. However, when mucinous lesions due to LAMNs, HAMNs, or mucinous adenocarcinomas rupture, they usually present with progressive intraperitoneal spread, resulting in accumulation of both mucinous ascites and neoplastic cells—a clinical syndrome referred to as PMP.

PMP was originally described as intraperitoneal mucinous spread from a ruptured cystadenoma (now called LAMN), seeding the peritoneum with mucus-producing cells and leading to progressive accumulation of copious amounts of mucinous fluid.

 The recent PSOGI pathologic classification redefined PMP as a complex syndrome with unique biological behavior and described 3 categories: low grade, high grade, and high grade with signet-ring cells. However, acellular mucin was classified separately.

 Appendiceal cancers rarely spread outside the abdominal cavity, and when they do, they are most commonly seen in poorly differentiated or signet-ring cell cancers.

Surgical resection is the mainstay of treatment for all localized appendiceal mucinous neoplasms. Depending on the surgeon’s experience, an open or laparoscopic standard appendectomy procedure with the inclusion of the cuff of the cecum, without intruding on the ileocecal valve, is preferable. If the base of the appendix is involved, a partial resection of cecum with preservation of the ileocecal valve, resection of the ileocecal valve, or resection of the entire right colon may be necessary to enable clear surgical margins. While by some groups right hemicolectomy has been proposed for tumors that involve the periappendiceal area, measure 2 cm or larger, have high-grade histology, or present with perforation, we prefer to reserve right colectomy for tumors with high-grade histology or documented lymph node involvement.

 In patients presenting with clinically evident peritoneal disease, a diagnosis can be established by percutaneous biopsy of a peritoneal lesion, and appendectomy can be deferred to the time of definitive cytoreductive surgery.

The initial surgery for ruptured but localized appendiceal mucinous lesions can be limited to an appendectomy/right hemicolectomy with careful inspection of the abdominal cavity and biopsy of any suspicious peritoneal lesions. During the surgery, the goal should be to minimize tumor cell implantation of the abdomen and surgical wounds by thorough washing, cleaning, and irrigation.

 Advanced-stage, ruptured, and/or metastatic appendiceal mucinous neoplasms require additional surgical treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a specialized center.

Radical surgical removal of all abdominopelvic disease combined with administration of heated intraperitoneal chemotherapy has been developed as a comprehensive treatment approach for curative intent and has been utilized at centers with expertise in this disease.

 Efficacy of this approach depends on the ability to accomplish minimal residual disease, described as tumor deposits smaller than 2 to 2.5 mm after the cytoreductive surgery. The 2 most commonly used intraperitoneal chemotherapeutic agents have been 

 and oxaliplatin. The results of the only randomized trial comparing these 2 chemotherapeutic agents showed no difference in efficacy: 3-year survival was 73% in both groups, with similar postoperative complications and long-term adverse effects.

The role of preoperative chemotherapy in appendiceal mucinous neoplasms has been evaluated in nonrandomized studies with controversial results. This is mostly likely due to the retrospective nature of these studies, limitations of current imaging modalities, and lack of standard response criteria to assess peritoneal disease involvement.

 Retrospective studies suggest that optimal CRS and HIPEC treatment without preoperative systemic chemotherapy is appropriate for low‐grade appendiceal neoplasms. However, for high‐grade appendiceal adenocarcinomas, systemic preoperative chemotherapy should be considered.

 A potential advantage of neoadjuvant chemotherapy can be tumor volume reduction, which may lead to less extensive surgical procedures with improved organ preservation. Due to less-than-ideal accuracy of preoperative clinical exam and imaging studies, it has been difficult to assess the impact of neoadjuvant chemotherapy on the extent of cytoreductive surgery. Thus, surgical exploration offers the best approach to accurately evaluate this effect. In the results of one study, systemic chemotherapy administered prior to CRS/HIPEC for peritoneal mucinous adenocarcinoma of appendiceal origin showed a significant rate of histological response.

 The results of another study showed that neoadjuvant treatment utilizing systemic 5‐FU–based chemotherapy produced complete or near‐complete pathologic responses in patients with peritoneal mucinous carcinomatosis, making limited surgical resections possible.

Similarly, the impact of adjuvant chemotherapy following CRS/HIPEC in appendiceal mucinous neoplasms has not been well established due to rareness of this disease and lack of randomized trials. In the advanced-disease setting, available retrospective data suggest beneficial effect from systemic chemotherapy in moderate- to high‐grade appendiceal mucinous tumors but not in low‐grade mucinous neoplasms.

 In a large National Cancer Database study of 639 patients with metastatic low‐grade mucinous appendiceal adenocarcinoma, systemic chemotherapy did not show beneficial effect on overall survival (OS).

 However, in moderate- to high‐grade mucinous tumors, signet‐ring cell tumors, and all nonmucinous tumors of appendiceal origin, systemic chemotherapy has been shown to be beneficial.

 Similarly, in earlier studies from a small group of 17 patients with PMP, adjuvant therapy following cytoreductive surgery reported no OS benefit.

 However, in patients with moderate- to high‐grade or signet‐ring cell appendiceal tumors, adjuvant chemotherapy following complete cytoreductive surgery provided significant OS benefit.

 The molecular profile of this case does not match to any current FDA targeted therapy; however, the presence of the kinase-impaired 

 mutation highlights the need for additional clinical trials targeting specific hotspot mutations in highly mutated oncogenes, especially in the setting of basket trials for rare diseases.

Appendiceal mucinous lesions are rare and have considerable heterogeneity and a rising incidence. They can be nonneoplastic (simple mucoceles/retention cysts) or neoplastic (serrated polyps; low-grade or high-grade appendiceal mucinous neoplasms; mucinous adenocarcinomas with or without signet-ring cell features). Treatment is based on a lesion’s histology and extent. While early-stage, low-grade tumors can be effectively treated with surgical resection of the primary site, advanced-stage disease requires peritoneal debulking surgery and intraperitoneal chemotherapy. Treatment of advanced-stage and high-grade tumors requires further prospective trials evaluating the role of pre- and postoperative chemotherapy as an addition to CRS/HIPEC. Prospective randomized trials evaluating the impact of established chemotherapeutic agents, as well as the novel therapeutic agents targeting pathways involving KRAS, p53, GNAS, SMAD4, APC, ATM, PIK3CA, FBXW7, and BRAF, are desperately needed.

After 6 cycles of neoadjuvant FOLFOX/bevacizumab systemic therapy, the patient underwent cytoreductive surgery; it revealed a histologic response mostly consisting of HAMN findings with focal signet-ring cell differentiation on her surgical debulking specimen. Following her recovery from CRS/HIPEC, she received 6 more cycles of adjuvant systemic therapy with FOLFOX/bevacizumab. Currently, she has no evidence of disease recurrence.

The authors have no significant financial interest in or other relationship with the manufacturer of any product or provider of any service mentioned in this article.

1. Shaib WL, Assi R, Shamseddine A, et al. Appendiceal mucinous neoplasms: diagnosis and management. 

. 2017;22(9):1107-1116. doi:10.1634/theoncologist.2017-0081

2. Smeenk RM, van Velthuysen MLF, Verwaal VJ, Zoetmulder FAN. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196-201. doi:10.1016/j.ejso.2007.04.002

3. McCusker ME, Coté TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population‐based study from the Surveillance, Epidemiology and End Results Program, 1973-1998. Cancer. 2002;94(12):3307-3312. doi:10.1002/cncr.10589

4. Carr NJ, Cecil TD, Mohamed F, et al; Peritoneal Surface Oncology Group International. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. 

. 2016;40(1):14-26. doi:10.1097/PAS.0000000000000535

5. MIsdraji J, Carr NJ, Pai RK. Appendiceal mucinous neoplasm. In: WHO Classification of Tumours Editorial Board. 

WHO Classification of Tumours: Digestive System Tumours

, 5th ed. International Agency for Research on Cancer;2019:144-146.

6. MIsdraji J, Carr NJ, Pai RK. Appendiceal adenocarcinoma. In: WHO Classification of Tumours Editorial Board. 

. 5th ed. International Agency for Research on Cancer; 2019:147-148.

7. Carr NJ, Bibeau F, Bradley RF, et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. 

. 2017;71(6):847-858. doi:10.1111/his.13324

8. Ahadi M, Sokolova A, Brown I, Chou A, Gill AJ. The 2019 World Health Organization Classification of appendiceal, colorectal and anal canal tumours: an update and critical assessment. 

. 2021;53(4):454-461. doi:10.1016/j.pathol.2020.10.010

9. Chou Y-Y, Jeng Y-M, Kao H-L, Chen T-J, Mao T-L, Lin M-C. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin. 

2003;43(2):151-156. doi:10.1046/j.1365-2559.2003.01687.x

10. Seidman JD, Elsayed AM, Sobin LH, Favassoli FA.Association of mucinous tumors of the ovary and appendix. a clinicopathologic study of 25 cases. 

. 1993;17(1):22-34. doi:10.1097/00000478-199301000-00003

11 Prayson RA. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry. 

 1999;3(1):11-18. doi:10.1016/s1092-9134(99)80004-5

12. Vang R, Gown AM, Barry TS, et al.Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases.

. 2006;30(9):1130-1139. doi:10.1097/01.pas.0000213281.43036.bb

13. Chu PG, Chung L, Weiss LM, Lau SK.Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases.

. 2011;35(12):1830-1836. doi:10.1097/PAS.0b013e3182299c25

14. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. 

. 2005;47(3):231-247. doi:10.1111/j.1365-2559.2005.02194.x

15. Vang R, Gown AM, Wu L-S-F, et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. 

 2006;19(11):1421-1428. doi:10.1038/modpathol.3800698

16. Kaimaktchiev V, Teracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. 

 2004;17(11):1392-1399. doi:10.1038/modpathol.3800205

17. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. 

. 2003;27(3):303-310. doi:10.1097/00000478-200303000-00003

18. Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. 

. 2011;35(6):816-826. doi:10.1097/PAS.0b013e318216c112

19. FitzPatrick DR, Carr IM, McLaren L, et al. Identification of SATB2 as the cleft palate gene on 2q32-q33. 

2003;12(19):2491-2501. doi:10.1093/hmg/ddg248

20. Li Z, Roth R, Rock JB, et al. Dual immunostain with SATB2 and CK20 differentiates appendiceal mucinous neoplasms from ovarian mucinous neoplasms.

. 2017;147(5):484-491. doi:10.1093/ajcp/aqx023

21. Misdraji J, Carr NJ, Pai RK. Appendiceal serrated lesions and polyps. In: WHO Classification of Tumours Editorial Board. 

, 5th ed. International Agency for Research on Cancer; 2019:141-143.

22. Liao X, Vavinskaya V, Sun K, et al. Mutation profile of high-grade appendiceal mucinous neoplasm. 

. 2020;76(3):461-469. doi:10.1111/his.13986

23. Mikaeel RR, Young JP, Tapia Rico G, et al. Immunohistochemistry features and molecular pathology of appendiceal neoplasms. 

. Published online February 11, 2021. doi:10.1080/10408363.2021.1881756

24. Hara K, Saito T, Hayashi T, et al. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix. 

. 2015;211(9):657-664. doi:10.1016/j.prp.2015.06.004

25. Taggart MW, Galbincea J, Mansfield P, et al. High-level microsatellite instability in appendiceal carcinomas. 

. 2013;37(8):1192-1200. doi:10.1097/PAS.0b013e318282649b

26. Yao Z, Yaeger R, Rodrik-Outmezguine VS, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. 

. 2017;548(7666):234-238. doi:10.1038/nature23291

27. Cope NJ, Novak B, Liu Z, et al. Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling. 

. 2020;295(8):2407-2420. doi:10.1074/jbc.RA119.011536

28. Zheng G, Tseng L-H, Chen G, et al. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. 

. 2015;15:779. doi:10.1186/s12885-015-1811-y

29. Landen S, Bertrand C, Maddern GJ, et al. Appendiceal mucoceles and pseudomyxoma peritonei. 

30. Isaacs KL, Warshauer DM. Mucocele of the appendix: computed tomographic, endoscopic, and pathologic correlation. 

31. Mourad FH, Hussein M, Bahlawan M, Haddad M, Tawil A.
Intestinal obstruction secondary to appendiceal mucocele. 

. 1999;44(8):1594-1598. doi:10.1023/a:1026615010989

32. Sugarbaker PH, Ronnett BM, Archer A, et al. Pseudomyxoma peritonei syndrome.


33. Baratti D, Kusamura S, Milione M, Bruno F, Guaglio M, Deraco M. Validation of the recent PSOGI pathological classification of pseudomyxoma peritonei in a single-center series of 265 patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

. 2018;25(2):404-413. doi:10.1245/s10434-017-6252-1

34. González‐Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg. 2004;91(3):304-311. doi:10.1002/bjs.4393

35. Barrios P, Losa F, Gonzalez-Moreno S, et al. Recommendations in the management of epithelial appendiceal neoplasms and peritoneal dissemination from mucinous tumors (pseudomyxoma peritonei). 

. 2016;18(5):437-448. doi:10.1007/s12094-015-1413-9

36. Chicago Consensus Working Group.The Chicago Consensus on peritoneal surface malignancies: management of appendiceal neoplasms. 

. 2020;27(6):1753-1760. doi:10.1245/s10434-020-08316-w

37. Moaven O, Votanopoulos KI, Shen P, et al. Health-related quality of life after cytoreductive surgery/HIPEC for mucinous appendiceal cancer: results of a multicenter randomized trial comparing oxaliplatin and mitomycin.

. 2020;27(3):772-780. doi:10.1245/s10434-019-08064-6

38. Esquivel J, Chua TC, Stojadinovic A, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi‐institutional study. J Surg Oncol. 2010;102(6):565-570. doi:10.1002/jso.21601

39. Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. 

. 2010;102(6):576-581. doi:10.1002/jso.21679

40. Shaib WL, Assi R, Shamseddine A, et al. Appendiceal mucinous neoplasms: diagnosis and management.

. 2017;22(9):1107-1116. doi:10.1634/theoncologist.2017-0081

41. Bijelic L, Kumar AS, Stuart OA, et al. Systemic chemotherapy prior to cytoreductive surgery and HIPEC for carcinomatosis from appendix cancer: impact on perioperative outcomes and short-term survival. 

. 2012;2012:163284. doi:10.1155/2012/163284

42. Asare EA, Compton CC, Hanna NN, et al. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: analysis of the National Cancer Data Base. 

. 2016;122(2):213‐222. doi:10.1002/cncr.29744

43. Lu P, Fields AC, Meyerhardt JA, et al. Systemic chemotherapy and survival in patients with metastatic low‐grade appendiceal mucinous adenocarcinoma. 

. 2019;120(3):446‐451. doi:10.1002/jso.25599

44. Shapiro JF, Chase JL, Wolff RA, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single‐institution experience. 

. 2010;116(2):316‐322. doi:10.1002/cncr.24715

45. Lieu CH, Lambert LA, Wolff RA, et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. 

. 2012;23(3):652‐658. doi:10.1093/annonc/mdr279

46. Uemura M, Qiao W, Fournier K, et al. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. 

. 2017;17(1):331. doi:10.1186/s12885-017-3327-0

47. Smith JW, Kemeny N, Caldwell C, Banner P, Sigurdson E, Huvos A. Pseudomyxoma peritonei of appendiceal origin. the Memorial Sloan‐Kettering Cancer Center experience. 

. 1992;70(2):396‐401. doi:10.1002/1097-0142(19920715)70:2<396::aid-cncr2820700205>3.0.co;2-a

48. Kolla BC, Petersen A, Chengappa M, et al. Impact of adjuvant chemotherapy on outcomes in appendiceal cancer. 

. 2020;9(10):3400-3406. doi:10.1002/cam4.3009

Mehmet Sitki Copur, MD, and colleagues examine the case of a 65-year-old patient with appendiceal mucinous neoplasms of the appendix who was treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Mucinous Adenocarcinoma of the Appendix With Histologic Response to Neoadjuvant Chemotherapy: Review of Histologic and Clinical Spectrum of Epithelial Neoplastic Mucinous Lesions of the Appendix

The phase 3 KEYNOTE-826 trial (NCT03635567), which examined pembrolizumab (Keytruda) plus platinum-based chemotherapy, with or without bevacizumab (Avastin), met its dual primary end points in a population of patients with persistent, recurrent, or metastatic cervical cancer in the first-line setting, according to a press release from drug developer Merck.

The results of the study’s interim analysis highlighted that combination yielded statistically significant and clinically meaningful improvements in the dual primary end points of overall survival (OS) and progression-free survival (PFS).

“Despite progress with prevention and screening, cervical cancer continues to be a major health problem, often affecting younger and middle-aged women,” Roy Baynes, MD, PhD, senior vice president, head of global clinical development, and chief medical officer at Merck Research Laboratories, said in a press release. “Women diagnosed with metastatic cervical cancer have a particularly poor prognosis, and there is an urgent need for new treatment options.”

The randomized, triple-blind, phase 3 trial enrolled adult patients with persistent, recurrent, or metastatic disease who did not previously receive systemic chemotherapy and were no longer candidates for curative treatments such as surgery and/or radiation.

A total of 617 patients were enrolled and randomized to receive either pembrolizumab 200 mg intravenously or placebo plus investigator’s choice of 1 of the platinum-based chemotherapy regimens on day 1 of each 21-day cycle for up to 35 cycles. The chemotherapy regimens included paclitaxel (175 mg/m2) plus cisplatin (50 mg/m2) with or without bevacizumab (15 mg/kg); or paclitaxel (175 mg/m2) plus carboplatin Area Under the Curve (AUC) 5 with or without bevacizumab (15 mg/kg). The control group was treated with placebo plus investigator's choice of platinum-based chemotherapy.

Secondary end points of the trial included objective response rate, duration of response, and safety.

Merck’s press release announced positive data from the KEYNOTE-826 trial investigating pembrolizumab plus chemotherapy with or without bevacizumab for patients with cervical cancer.

ONCOLOGY Vol 35, Issue 5 | June 2021

Product Profile

Expert Commentary on The Product Profile of Belantamab Mafodotin

Editorial

Next-Generation Sequencing for Advanced Pancreatic Cancer: A Technology Whose Time Has NOT Come

Clinical Quandaries

Hand-Foot Skin Reaction Secondary to Sunitinib in a Patient With Metastatic Clear Cell Renal Cell Carcinoma

Interview

Tracing Steps of Clinical Research in Lung Cancer

Perspective

Prostate Cancer Focal Therapy Has Made Great Strides and the Future Remains Bright

Review Article

Primary Focal Therapy for Localized Prostate Cancer: A Review of the Literature

Review Article

Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates

Original Research

Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community Physicians